Clover to Participate in Credit Suisse Asia Healthcare Corporate Day

Clover to Participate in Credit Suisse Asia Healthcare Corporate Day GlobeNewswire June 07, 2022

SHANGHAI, China, June 07, 2022 (GLOBE NEWSWIRE) -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, today announced its participation in Credit Suisse’s Asia Healthcare Corporate Day, June 14-16, 2022.

Details of the conference and management participation are as follows:   

Credit Suisse Asia Healthcare Corporate Day 2022
One-on-one and small group meetings: June 14 – 16, 2022
Participants: Management team and IR
For more information, please contact your Credit Suisse representative.

About Clover Biopharmaceuticals 
Clover Biopharmaceuticals is a global clinical-stage biotechnology company committed to developing novel vaccines and biologic therapeutic candidates. The Trimer-Tag™ technology platform is a product development platform for the creation of novel vaccines and biologic therapies. Clover leveraged the Trimer-Tag™ technology platform to become a COVID-19 vaccine developer and created SCB-2019 (CpG 1018/Alum) to address the COVID-19 pandemic caused by SARS-CoV-2. 

For more information, please visit Clover’s website: www.cloverbiopharma.com and follow the company on LinkedIn.

Clover Biopharmaceuticals:

Cindy Min 
SVP, Public Affairs 
media@cloverbiopharma.com 

Naomi Eichenbaum 
VP, Investor Relations 
investors@cloverbiopharma.com


Primary Logo

This website is best viewed using the latest versions of web browsers.